BlackThorn Therapeutics CEO and leadership

Bill Martin is a Chief Executive Officer at BlackThorn Therapeutics. He has experience at Merck & Co. Inc. and has worked as Head:Research Portfolio Planning at THERAVANCE, President/COO/Co-founder at BlackThorn Therapeutics, and Chief Scientific Officer at BlackThorn Therapeutics. Bill studied at Brown University and Swarthmore College.

Annette Madrid is a Chief Medical Officer at BlackThorn Therapeutics and Independent Consultant at Self-employed and is based in San Francisco, California. She has worked as Independent Consultant at Jazz Pharmaceuticals and Nektar Therapeutics; Attending Physician at Riverview Hospital For Children & Youth; and Independent Clinical, Medical and Safety Consultant at Pharmaceutical companies in the San Francisco Bay Area. Annette studied at New Mexico State University between 1980 and 1984, University of New Mexico School of Medicine between 1992 and 1995, and The University of New Mexico UNM.

Jane Tiller is the chief medical officer of Neumora. She brings to the company deep experience in clinical psychiatry and drug development. Most recently, she was head of European markets, Australia and Canada, at Bristol-Myers Squibb, where she oversaw all medical functions. During her tenure at BMS, Jane also served as vice president of global medical for neuroscience, virology and immunoscience and as full development team lead for the Alzheimer’s program. Prior to joining BMS, Jane held positions of increasing responsibility at Cephalon, and, as vice president of neuroscience and pain, was responsible for all clinical development activities including programs for schizophrenia, bipolar disorder, anxiety and sleep disorders.

Prior to joining industry, Jane was clinical director at the Maudsley Hospital, London, where she was responsible for clinical services for Southwark and across several London teaching hospitals. She was a consultant psychiatrist (attending) and honorary senior lecturer.

Jane received her medical degree from the Glasgow University Medical School, an MBA from Drexel University and an MPhil from the University of Pennsylvania.

Bill Martin is a Chief Executive Officer at BlackThorn Therapeutics. He has experience at Merck & Co. Inc. and has worked as Head:Research Portfolio Planning at THERAVANCE, President/COO/Co-founder at BlackThorn Therapeutics, and Chief Scientific Officer at BlackThorn Therapeutics. Bill studied at Brown University and Swarthmore College.